NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
Taking everything into account, ARCT scores 3 out of 10 in our fundamental rating. ARCT was compared to 551 industry peers in the Biotechnology industry. ARCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARCT shows excellent growth, but is valued quite expensive already.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -20.56% | ||
ROE | -29.18% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.06 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.53 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.64 | ||
Quick Ratio | 5.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:ARCT (8/4/2025, 2:54:20 PM)
12.225
-0.08 (-0.61%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.31 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.42 | ||
P/tB | 1.42 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -20.56% | ||
ROE | -29.18% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.06 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 15.84% | ||
Cap/Sales | 0.38% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.64 | ||
Quick Ratio | 5.64 | ||
Altman-Z | 0.53 |